Stratifying Mortality Risk Using Physical Activity as Measured by Wearable Sensors
Munich Re assessed the effectiveness of physical activity as measured by wearable sensors in stratifying the mortality risk profile of a U.S. population-based dataset provided by Vivametrica. Munich Re examined the dataset, performed classical actuarial mortality analysis and used survival analysis and machine learning techniques to evaluate the extent to which physical activity predicts mortality.
We began 2018 with some promising news on cancer: A simple blood test can now detect disease in eight common sites. Called the CancerSEEK test, it was developed at the Johns Hopkins Kimmel Cancer Center, and may herald a new age in cancer medicine
Insurers design critical illness policies with the intention being to cover medical conditions that are likely to have a life-changing impact on the life insured, with payment alleviating financial pressure as recovery and adjustment to an altered way of life take place. Should insurers include lower risk prostate cancer in such products or are they well positioned to exclude these altogether, considering the favorable outcome?
Increasingly, computer templates are making binding underwriting decisions through information that is programmed in with final decisions virtually unappealable. It’s a frustrating situation that is taking the human element out of a very human situation of health and risk assessment.
Collaboration Can Bring Digital Innovation to Life Insurance
There is a view that the life insurance business needs to change or to innovate in order to remain relevant and reach new customers; if incumbent players don’t make an environment that appeals to new customers, someone else will step in and do it in their place.
Cost-Benefit Analysis of Underwriting Screening for Opioid Risks
The question we hear from underwriters is: is it financially feasible to screen all life applicants for opioid use? The intention of this paper is to provide context for these concerns by exploring various screening options, and to provide a cost-benefit analysis that can assist underwriting departments in determining when to use such screening tools.